; and (2) by adding at the end, the following new subclause: (IV) For 2020 through 2024, the productivity adjustment described in subclause (II) shall be zero for a payment system for any year in which the Medicare Payment Advisory Commission established under section 1805 estimates that payments provided under such payment system, on an aggregate national basis, exceed costs, on an aggregate national basis, by 3.0 percent or less. . (e) Payment for new and innovative drugs and biologicals that are renal dialysis services Section 1881(b)(14) of the Social Security Act ( 42 U.S.C. 1395ww(b)(14) ), as amended by subsections (a), (b), and (c), is further amended by adding the following new subparagraph: (N) Payment for new and innovative drugs, biologicals, and devices that are renal dialysis services (i) In general For drugs or biologicals determined to be within a functional category, the Secretary, in consultation with stakeholders, shall ensure that the single payment amount is adequate to cover the cost of new innovative drugs or biologicals and increase the single payment amount if it is not. The Secretary shall use the cost and utilization data collected during the two-year transitional period, as set forth in the final regulation entitled Medicare Program